{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:36:51Z","timestamp":1793659011060,"version":"4.5.1"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL) in the phase III GALLIUM trial (NCT01332968). Patients had stage III\/IV (or stage II with bulky disease), splenic, nodal, or extranodal MZL requiring treatment. Patients were randomized 1:1 to receive G- or R-chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone; cyclophosphamide, vincristine, and prednisone; or bendamustine, allocated at patient level). Patients with complete\/partial response at the end of induction (EOI) received G\/R maintenance. Investigator-assessed progression-free survival (PFS), other time-to-event endpoints, response, and safety were assessed. Overall, 195 patients with MZL were included in this analysis: G-chemotherapy (n = 99), R-chemotherapy (n = 96). Median observation time: 59.3 months. No meaningful difference was observed between arms for PFS (4-y PFS rates: G-chemotherapy, 72.6%; R-chemotherapy, 64.1%), other time-to-event endpoints, or EOI response rates (by computed tomography [CT; G-chemotherapy, 81.8%; R-chemotherapy, 81.3%] and positron emission tomography CT [G-chemotherapy, 79.2%; R-chemotherapy, 87.5%]). All patients experienced \u22651 adverse event (AE). G-chemotherapy was associated with a higher incidence of grade 3\u20135 (86.1% versus 77.4%), grade 5 (14.9% versus 9.7%), and serious (66.3% versus 51.6%) AEs versus R-chemotherapy. Both arms had a higher incidence of grade 3\u20135 and serious AEs than patients with follicular lymphoma (GALLIUM), with G-chemotherapy being less tolerable than R-chemotherapy. Based on the observed tolerability of G-chemotherapy versus R-chemotherapy, and the comparable efficacy of G-chemotherapy and R-chemotherapy in this analysis, G-chemotherapy cannot be recommended as first-line treatment for MZL.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000699","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T19:32:56Z","timestamp":1645731176000},"page":"e699","source":"Crossref","is-referenced-by-count":25,"title":["Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial"],"prefix":"10.1002","volume":"6","author":[{"given":"Michael","family":"Herold","sequence":"first","affiliation":[{"name":"Helios Klinikum Erfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University Hospital Munich, Germany"},{"name":"Institute of Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[{"name":"Department of Hematology, Universitaire Ziekenhuizen Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Bournemouth General Hospital, Bournemouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Pocock","sequence":"additional","affiliation":[{"name":"East Kent Hospitals NHS Trust, Canterbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Rosta","sequence":"additional","affiliation":[{"name":"Department of Haematology, Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina G.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knapp","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University Hospital Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Marcus","sequence":"additional","affiliation":[{"name":"HCA Healthcare, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"R1-20231126","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CMAR.S133291","article-title":"Management of relapsed\/refractory marginal zone lymphoma: focus on ibrutinib.","volume":"10","author":"Denlinger","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R2-20231126","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011.","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"key":"R3-20231126","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R4-20231126","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"R5-20231126","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"key":"R6-20231126","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3816\/CLM.2004.n.005","article-title":"Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.","volume":"4","author":"Arcaini","year":"2004","journal-title":"Clin Lymphoma"},{"key":"R7-20231126","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study.","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"key":"R8-20231126","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy.","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"key":"R9-20231126","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma.","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"R10-20231126","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"R11-20231126","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"R12-20231126","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.","volume":"122","author":"Golay","year":"2013","journal-title":"Blood"},{"key":"R13-20231126","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma.","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20231126","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R15-20231126","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"key":"R16-20231126","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study.","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"key":"R17-20231126","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"R18-20231126","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-99-115167","article-title":"Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: four-year results from the Phase III GALLIUM study.","volume":"132","author":"Townsend","year":"2018","journal-title":"Blood"},{"key":"R19-20231126","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"R20-20231126","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3109\/10428194.2014.975801","article-title":"Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.","volume":"56","author":"Lossos","year":"2015","journal-title":"Leuk Lymphoma"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:05:26Z","timestamp":1702922726000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000699","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]}}}